These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 12673700

  • 21. [Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications].
    Wülfing C, Eltze E, Von Struensee D, Wülfing P, Bode ME, Bettendorf O, Piechota H, Hertle L.
    Aktuelle Urol; 2004 Aug; 35(4):331-8. PubMed ID: 15459875
    [Abstract] [Full Text] [Related]

  • 22. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression.
    Quentin T, Schlott T, Korabiowska M, Käthei N, Zöller G, Glaser F, Kunze E.
    Anticancer Res; 2004 Aug; 24(5A):2745-56. PubMed ID: 15517881
    [Abstract] [Full Text] [Related]

  • 23. Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators.
    Korkolopoulou P, Givalos N, Saetta A, Goudopoulou A, Gakiopoulou H, Thymara I, Thomas-Tsagli E, Patsouris E.
    Hum Pathol; 2005 Aug; 36(8):899-907. PubMed ID: 16112007
    [Abstract] [Full Text] [Related]

  • 24. Systemic chemotherapy in locally advanced and/or metastatic bladder cancer.
    Pectasides D, Pectasides M, Economopoulos T.
    Cancer Treat Rev; 2006 Oct; 32(6):456-70. PubMed ID: 16935429
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG).
    Saint F, Le Frere Belda MA, Quintela R, Hoznek A, Patard JJ, Bellot J, Popov Z, Zafrani ES, Abbou CC, Chopin DK, de Medina SG.
    Eur Urol; 2004 Apr; 45(4):475-82. PubMed ID: 15041112
    [Abstract] [Full Text] [Related]

  • 29. Update on chemotherapy for advanced bladder cancer.
    Rosenberg JE, Carroll PR, Small EJ.
    J Urol; 2005 Jul; 174(1):14-20. PubMed ID: 15947569
    [Abstract] [Full Text] [Related]

  • 30. Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer.
    Kramer MW, Kuczyk MA, Hennenlotter J, Serth J, Schilling D, Stenzl A, Merseburger AS.
    Oncol Rep; 2008 Dec; 20(6):1403-8. PubMed ID: 19020721
    [Abstract] [Full Text] [Related]

  • 31. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder.
    Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y.
    Urol Oncol; 2007 Dec; 25(6):468-75. PubMed ID: 18047954
    [Abstract] [Full Text] [Related]

  • 32. Tumour growth inhibition by an imidazoquinoline is associated with c-Myc down-regulation in urothelial cell carcinoma.
    Liu H, Schwartz MJ, Hwang DH, Scherr DS.
    BJU Int; 2008 Apr; 101(7):894-901. PubMed ID: 18241249
    [Abstract] [Full Text] [Related]

  • 33. Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
    Ecke TH, Schlechte HH, Schulze G, Lenk SV, Loening SA.
    Anticancer Res; 2005 Apr; 25(1B):635-41. PubMed ID: 15816639
    [Abstract] [Full Text] [Related]

  • 34. Expression of lung resistance-related protein in transitional cell carcinoma of bladder.
    Zhu Y, Kong C, Zeng Y, Sun Z, Gao H.
    Urology; 2004 Apr; 63(4):694-8. PubMed ID: 15072883
    [Abstract] [Full Text] [Related]

  • 35. Effect of various natural products on growth of bladder cancer cells: two promising mushroom extracts.
    Konno S.
    Altern Med Rev; 2007 Mar; 12(1):63-8. PubMed ID: 17397268
    [Abstract] [Full Text] [Related]

  • 36. Deletions of p15 and p16 in schistosomal bladder cancer correlate with transforming growth factor-alpha expression.
    Swellam M, El-Aal AA, AbuGabel KM.
    Clin Biochem; 2004 Dec; 37(12):1098-104. PubMed ID: 15589816
    [Abstract] [Full Text] [Related]

  • 37. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer.
    George B, Datar RH, Wu L, Cai J, Patten N, Beil SJ, Groshen S, Stein J, Skinner D, Jones PA, Cote RJ.
    J Clin Oncol; 2007 Dec 01; 25(34):5352-8. PubMed ID: 18048815
    [Abstract] [Full Text] [Related]

  • 38. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer.
    Matsumoto K, Satoh T, Irie A, Ishii J, Kuwao S, Iwamura M, Baba S.
    Urology; 2008 Aug 01; 72(2):444-9. PubMed ID: 18313120
    [Abstract] [Full Text] [Related]

  • 39. The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy.
    Aparicio AM, Elkhouiery AB, Quinn DI.
    Urol Clin North Am; 2005 May 01; 32(2):217-30, vii. PubMed ID: 15862619
    [Abstract] [Full Text] [Related]

  • 40. Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancer.
    Dhawan D, Ramos-Vara JA, Stewart JC, Zheng R, Knapp DW.
    Urol Oncol; 2009 May 01; 27(3):284-92. PubMed ID: 18562222
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.